title: Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.
abstract: In recent years with the development of targeted agents such as bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus, the treatment of metastatic renal cell carcinoma has changed dramatically. In clinical practice, sunitinib and bevacizumab are reserved for first-line treatment, but despite various guidelines, optimal treatment is still uncertain. We present, for the first time, a case of a good response to second-line bevacizumab and interferon-alpha in a patient who failed classical sunitinib treatment.
authors: Oncologia Medica, Istituto Oncologico Veneto - IRCCS, Padova, Italy.
authors: Davide
authors: D
authors: Pastorelli
authors: Fable
authors: F
authors: Zustovich
authors: Giovanni
authors: G
authors: Faggioni
authors: Stefania
authors: S
authors: Zovato
authors: Martin
authors: M
authors: Donach
authors: Ornella
authors: O
authors: Nicoletto
authors: Miriam
authors: M
authors: Farina
authors: Lara
authors: L
authors: Furini
authors: Renato
authors: R
authors: Ceravolo
authors: Paolo
authors: P
authors: Carli
authors: Giuseppe
authors: G
authors: Lombardi
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D016898:Interferon-alpha / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008207:Lymphatic Metastasis; D011379:Prognosis; D011758:Pyrroles / Q000008:administration & dosage; D016879:Salvage Therapy; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007211:Indoles; D016898:Interferon-alpha; D011758:Pyrroles; D000068258:Bevacizumab; D000077210:Sunitinib